Actuations per day before and after an asthma exacerbation
| Budesonide–formoterol as needed | Maintenance budesonide with terbutaline as needed | |
| Patients | 12 | 15 |
| Budesonide use actuations | ||
| Use in the 14 days before an exacerbation | ||
| Mean±sd | 2.1±1.7 | 1.7±0.3 |
| Median (IQR) | 1.5 (0.9–2.4) | 1.7 (1.5–2.0) |
| Range (minimum–maximum) | 0.4–6.0 | 1.1–2.2 |
| Use in the 5 days before an exacerbation | ||
| Mean±sd | 2.4±1.6 | 2.0±0.4 |
| Median (IQR) | 1.7 (1.2–3.7) | 2.0 (1.8–2.2) |
| Range (minimum–maximum) | 0.8–5.2 | 1.2–2.4 |
| Use in the 14 days after an exacerbation | ||
| Mean±sd | 1.2±0.8 | 1.7±0.9 |
| Median (IQR) | 1.0 (0.9–1.3) | 1.9 (1.4–1.9) |
| Range (minimum–maximum) | 0.0–3.4 | 0.4–4.1 |
| Use in the 5 days after an exacerbation | ||
| Mean±sd | 1.5±0.7 | 1.9±1.2 |
| Median (IQR) | 1.5 (1.1–2.0) | 1.8 (1.1–1.9) |
| Range (minimum–maximum) | 0.0–2.4 | 0.4–5.4 |
| β2-agonist use actuations | ||
| Use in the 14 days before an exacerbation | ||
| Mean±sd | 2.1±1.7 | 1.9±1.6 |
| Median (IQR) | 1.5 (0.9–2.4) | 1.8 (0.7–2.9) |
| Range (minimum–maximum) | 0.4–6.0 | 0.0–5.9 |
| Use in the 5 days before an exacerbation | ||
| Mean±sd | 2.4±1.6 | 2.8±1.8 |
| Median (IQR) | 1.7 (1.2–3.7) | 2.8 (1.6–3.8) |
| Range (minimum–maximum) | 0.8–5.2 | 0.0–6.2 |
| Use in the 14 days after an exacerbation | ||
| Mean±sd | 1.2±0.8 | 1.6±1.4 |
| Median (IQR) | 1.0 (0.9–1.3) | 1.1 (0.4–2.8) |
| Range (minimum–maximum) | 0.0–3.4 | 0.0–4.1 |
| Use in the 5 days after an exacerbation | ||
| Mean±sd | 1.5±0.7 | 2.2±2.0 |
| Median (IQR) | 1.5 (1.1–2.0) | 2.0 (0.5–3.3) |
| Range (minimum–maximum) | 0.0–2.4 | 0.0–6.0 |
IQR: interquartile range.